nach oben

Die Diabetologie

Erschienen in:

10.03.2023 | Typ-2-Diabetes | Leitthema

Pathomechanismen der chronischen Nierenschädigung bei Diabetes und anderen Begleiterkrankungen

verfasst von: Maximilian J. Ganz, Katrin Bose, Carolin Herzog, S. Bender, Peter R. Mertens, Florian G. Scurt

Erschienen in: Die Diabetologie | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Zusammenfassung

Global leiden ca. 10 % aller Menschen an einer chronischen Niereninsuffizienz (CNI). Eine ihrer häufigsten Ursachen ist die diabetische Nephropathie, die bei ungefähr 30 % der Menschen mit Typ-1-Diabetes und bei ca. 40 % derjenigen mit Typ-2-Diabetes auftritt. Die Genese der diabetischen Nierenerkrankung bzw. der diabetischen Nephropathie ist multifaktoriell. Ein negatives Zusammenspiel vieler Einflussfaktoren (chronische Hyperglykämie, hämodynamische Dysregulation, zelluläre Veränderungen durch Modifikation des Epigenoms und die Entwicklung von reaktiven Sauerstoffradikalen), die sich gegenseitig aggravieren, mündet oftmals in einer irreversiblen renalen Schädigung. Neben den erwähnten Faktoren werden in dieser Übersichtsarbeit zusätzlich eine Auswahl an den mit dem Diabetes mellitus vergesellschafteten Komorbiditäten und deren Einfluss auf die Nierenfunktion vorgestellt.

de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM et al (2022) Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and kidney disease: improving global outcomes (KDIGO). Diabetes Care. https://doi.org/10.2337/dci22-0027CrossRefPubMedPubMedCentral

Afkarian M, Zelnick LR, Hall YN, Heagerty PJ, Tuttle K, Weiss NS et al (2016) Clinical manifestations of kidney disease among US adults with diabetes, 1988–2014. JAMA 316(6):602–610. https://doi.org/10.1001/jama.2016.10924CrossRefPubMedPubMedCentral

Levin A, Tonelli M, Bonventre J, Coresh J, Donner JA, Fogo AB et al (2017) Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet 390(10105):1888–1917. https://doi.org/10.1016/S0140-6736(17)30788-2CrossRefPubMed

Lameire NH, Levin A, Kellum JA, Cheung M, Jadoul M, Winkelmayer WC et al (2021) Harmonizing acute and chronic kidney disease definition and classification: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney Int 100(3):516–526. https://doi.org/10.1016/j.kint.2021.06.028CrossRefPubMed

Chapter 1: Definition and classification of CKD. Kidney Int Suppl (2011). 2013;3(1):19–62. https://doi.org/10.1038/kisup.2012.64.

Ruggenenti P, Porrini EL, Gaspari F, Motterlini N, Cannata A, Carrara F et al (2012) Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care 35(10):2061–2068. https://doi.org/10.2337/dc11-2189CrossRefPubMedPubMedCentral

Tonneijck L, Muskiet MH, Smits MM, van Bommel EJ, Heerspink HJ, van Raalte DH et al (2017) Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment. J Am Soc Nephrol 28(4):1023–1039. https://doi.org/10.1681/asn.2016060666CrossRefPubMedPubMedCentral

Oshima M, Shimizu M, Yamanouchi M, Toyama T, Hara A, Furuichi K et al (2021) Trajectories of kidney function in diabetes: a clinicopathological update. Nat Rev Nephrol 17(11):740–750. https://doi.org/10.1038/s41581-021-00462-yCrossRefPubMed

Tuttle KR, Agarwal R, Alpers CE, Bakris GL, Brosius FC, Kolkhof P et al (2022) Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney Int 102(2):248–260. https://doi.org/10.1016/j.kint.2022.05.012CrossRefPubMed

10.

Girndt M, Trocchi P, Scheidt-Nave C, Markau S, Stang A (2016) The prevalence of renal failure. Results from the German health interview and examination survey for adults, 2008–2011 (DEGS1). Dtsch Arztebl Int 113(6):85–91. https://doi.org/10.3238/arztebl.2016.0085CrossRefPubMedPubMedCentral

11.

Kovesdy CP (2011) Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl 12(1):7–11. https://doi.org/10.1016/j.kisu.2021.11.003CrossRef

12.

Alicic RZ, Rooney MT, Tuttle KR (2017) Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol 12(12):2032–2045. https://doi.org/10.2215/CJN.11491116CrossRefPubMedPubMedCentral

13.

Kato M, Natarajan R (2019) Epigenetics and epigenomics in diabetic kidney disease and metabolic memory. Nat Rev Nephrol 15(6):327–345. https://doi.org/10.1038/s41581-019-0135-6CrossRefPubMedPubMedCentral

14.

Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, Himmelfarb J et al (2013) Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol 24(2):302–308. https://doi.org/10.1681/ASN.2012070718CrossRefPubMedPubMedCentral

15.

Groop PH, Thomas MC, Moran JL, Waden J, Thorn LM, Makinen VP et al (2009) The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 58(7):1651–1658. https://doi.org/10.2337/db08-1543CrossRefPubMedPubMedCentral

16.

Wu B, Zhang S, Lin H, Mou S (2018) Prevention of renal failure in Chinese patients with newly diagnosed type 2 diabetes: A cost-effectiveness analysis. J Diabetes Investig 9(1):152–161. https://doi.org/10.1111/jdi.12653CrossRefPubMed

17.

Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR et al (2003) Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63(1):225–232. https://doi.org/10.1046/j.1523-1755.2003.00712.xCrossRefPubMed

18.

Jim B, Santos J, Spath F, Cijiang He J (2012) Biomarkers of diabetic nephropathy, the present and the future. Curr Diabetes Rev 8(5):317–328. https://doi.org/10.2174/157339912802083478CrossRefPubMed

19.

Pambianco G, Costacou T, Ellis D, Becker DJ, Klein R, Orchard TJ (2006) The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes 55(5):1463–1469. https://doi.org/10.2337/db05-1423CrossRefPubMed

20.

Ziyadeh FN, Wolf G (2008) Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabetes Rev 4(1):39–45. https://doi.org/10.2174/157339908783502370CrossRefPubMed

21.

Cooper ME (1998) Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 352(9123):213–219. https://doi.org/10.1016/S0140-6736(98)01346-4CrossRefPubMed

22.

Takiyama Y, Haneda M (2014) Hypoxia in diabetic kidneys. Biomed Res Int 2014:837421. https://doi.org/10.1155/2014/837421CrossRefPubMedPubMedCentral

23.

Nowotny K, Jung T, Hohn A, Weber D, Grune T (2015) Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. Biomolecules 5(1):194–222. https://doi.org/10.3390/biom5010194CrossRefPubMedPubMedCentral

24.

Uribarri J, Woodruff S, Goodman S, Cai W, Chen X, Pyzik R et al (2010) Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc 110(6):911–916. https://doi.org/10.1016/j.jada.2010.03.018CrossRefPubMedPubMedCentral

25.

Reidy K, Kang HM, Hostetter T, Susztak K (2014) Molecular mechanisms of diabetic kidney disease. J Clin Invest 124(6):2333–2340. https://doi.org/10.1172/JCI72271CrossRefPubMedPubMedCentral

26.

Snelson M, Tan SM, Clarke RE, de Pasquale C, Thallas-Bonke V, Nguyen TV et al (2021) Processed foods drive intestinal barrier permeability and microvascular diseases. Sci Adv. https://doi.org/10.1126/sciadv.abe4841CrossRefPubMedPubMedCentral

27.

Raman KG, Sappington PL, Yang R, Levy RM, Prince JM, Liu S et al (2006) The role of RAGE in the pathogenesis of intestinal barrier dysfunction after hemorrhagic shock. Am J Physiol Gastrointest Liver Physiol 291(4):G556–G565. https://doi.org/10.1152/ajpgi.00055.2006CrossRefPubMed

28.

Snelson M, Coughlan MT (2019) Dietary advanced glycation end products: digestion, metabolism and modulation of gut microbial ecology. Nutrients 11(2):215. https://doi.org/10.3390/nu11020215CrossRefPubMedPubMedCentral

29.

Garay-Sevilla ME, Beeri MS, de la Maza MP, Rojas A, Salazar-Villanea S, Uribarri J (2020) The potential role of dietary advanced glycation endproducts in the development of chronic non-infectious diseases: a narrative review. Nutr Res Rev 33(2):298–311. https://doi.org/10.1017/S0954422420000104CrossRefPubMed

30.

Yacoub R, Nugent M, Cai W, Nadkarni GN, Chaves LD, Abyad S et al (2017) Advanced glycation end products dietary restriction effects on bacterial gut microbiota in peritoneal dialysis patients; a randomized open label controlled trial. PLoS ONE 12(9):e184789. https://doi.org/10.1371/journal.pone.0184789CrossRefPubMedPubMedCentral

31.

Ramezani A, Raj DS (2014) The gut microbiome, kidney disease, and targeted interventions. J Am Soc Nephrol 25(4):657–670. https://doi.org/10.1681/ASN.2013080905CrossRefPubMed

32.

Zhang S, Cai Y, Meng C, Ding X, Huang J, Luo X et al (2021) The role of the microbiome in diabetes mellitus. Diabetes Res Clin Pract 172:108645. https://doi.org/10.1016/j.diabres.2020.108645CrossRefPubMed

33.

Ma J, Chadban SJ, Zhao CY, Chen X, Kwan T, Panchapakesan U et al (2014) TLR4 activation promotes podocyte injury and interstitial fibrosis in diabetic nephropathy. PLoS One 9(5):e97985. https://doi.org/10.1371/journal.pone.0097985CrossRefPubMedPubMedCentral

34.

Diener C, Reyes-Escogido ML, Jimenez-Ceja LM, Matus M, Gomez-Navarro CM, Chu ND et al (2020) Progressive shifts in the gut microbiome reflect prediabetes and diabetes development in a treatment-naive mexican cohort. Front Endocrinol (Lausanne) 11:602326. https://doi.org/10.3389/fendo.2020.602326CrossRefPubMed

35.

Reichardt N, Duncan SH, Young P, Belenguer A, McWilliam Leitch C, Scott KP et al (2014) Phylogenetic distribution of three pathways for propionate production within the human gut microbiota. ISME J 8(6):1323–1335. https://doi.org/10.1038/ismej.2014.14CrossRefPubMedPubMedCentral

36.

Mosterd CM, Kanbay M, van den Born BJH, van Raalte DH, Rampanelli E (2021) Intestinal microbiota and diabetic kidney diseases: the role of microbiota and derived metabolites inmodulation of renal inflammation and disease progression. Best Pract Res Clin Endocrinol Metab 35(3):101484. https://doi.org/10.1016/j.beem.2021.101484CrossRefPubMed

37.

Kashyap S, Belfort R, Gastaldelli A, Pratipanawatr T, Berria R, Pratipanawatr W et al (2003) A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes 52(10):2461–2474. https://doi.org/10.2337/diabetes.52.10.2461CrossRefPubMed

38.

Belfort R, Mandarino L, Kashyap S, Wirfel K, Pratipanawatr T, Berria R et al (2005) Dose-response effect of elevated plasma free fatty acid on insulin signaling. Diabetes 54(6):1640–1648. https://doi.org/10.2337/diabetes.54.6.1640CrossRefPubMed

39.

Thomas MC, Rosengard-Barlund M, Mills V, Ronnback M, Thomas S, Forsblom C et al (2006) Serum lipids and the progression of nephropathy in type 1 diabetes. Diabetes Care 29(2):317–322. https://doi.org/10.2337/diacare.29.02.06.dc05-0809CrossRefPubMed

40.

Moore KJ, Fisher EA (2013) Dysfunctional HDL takes its toll in chronic kidney disease. Immunity 38(4):628–630. https://doi.org/10.1016/j.immuni.2013.03.006CrossRefPubMed

41.

DeFronzo RA, Reeves WB, Awad AS (2021) Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. Nat Rev Nephrol 17(5):319–334. https://doi.org/10.1038/s41581-021-00393-8CrossRefPubMed

42.

Mora-Fernandez C, Dominguez-Pimentel V, de Fuentes MM, Gorriz JL, Martinez-Castelao A, Navarro-Gonzalez JF (2014) Diabetic kidney disease: from physiology to therapeutics. J Physiol 592(18):3997–4012. https://doi.org/10.1113/jphysiol.2014.272328CrossRefPubMedPubMedCentral

43.

Alicic RZ, Neumiller JJ, Johnson EJ, Dieter B, Tuttle KR (2019) Sodium-glucose cotransporter 2 inhibition and diabetic kidney disease. Diabetes 68(2):248–257. https://doi.org/10.2337/dbi18-0007CrossRefPubMed

44.

Vallon V, Gerasimova M, Rose MA, Masuda T, Satriano J, Mayoux E et al (2014) SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol 306(2):F194–F204. https://doi.org/10.1152/ajprenal.00520.2013CrossRefPubMed

45.

Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ (2016) Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: Cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134(10):752–772. https://doi.org/10.1161/CIRCULATIONAHA.116.021887CrossRefPubMed

46.

Marton A, Kaneko T, Kovalik JP, Yasui A, Nishiyama A, Kitada K et al (2021) Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation. Nat Rev Nephrol 17(1):65–77. https://doi.org/10.1038/s41581-020-00350-xCrossRefPubMed

47.

Palmer BF, Clegg DJ (2022) Kidney-protective effects of SGLT2 inhibitors. Clin J Am Soc Nephrol. https://doi.org/10.2215/CJN.09380822CrossRefPubMedPubMedCentral

48.

Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T et al (2016) Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 387(10017):435–443. https://doi.org/10.1016/S0140-6736(15)00805-3CrossRefPubMed

49.

Parving HH, Andersen AR, Smidt UM, Svendsen PA (1983) Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1(8335):1175–1179. https://doi.org/10.1016/s0140-6736(83)92462-5CrossRefPubMed

50.

Patney V, Whaley-Connell A, Bakris G (2015) Hypertension management in diabetic kidney disease. Diabetes Spectr 28(3):175–180. https://doi.org/10.2337/diaspect.28.3.175CrossRefPubMedPubMedCentral

51.

Ruggenenti P, Cravedi P, Remuzzi G (2010) The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol 6(6):319–330. https://doi.org/10.1038/nrneph.2010.58CrossRefPubMed

52.

Warren AM, Knudsen ST, Cooper ME (2019) Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies. Expert Opin Ther Targets 23(7):579–591. https://doi.org/10.1080/14728222.2019.1624721CrossRefPubMed

53.

Tuttle KR, Puhlman ME, Cooney SK, Short RA (2002) Effects of amino acids and glucagon on renal hemodynamics in type 1 diabetes. Am J Physiol Renal Physiol 282(1):F103–F112. https://doi.org/10.1152/ajprenal.00155.2001CrossRefPubMed

54.

Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB et al (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345(12):851–860. https://doi.org/10.1056/NEJMoa011303CrossRefPubMed

55.

Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH et al (2001) Effects of iosartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345(12):861–869. https://doi.org/10.1056/NEJMoa011161CrossRefPubMed

56.

Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK (2008) Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358(23):2433–2446. https://doi.org/10.1056/NEJMoa0708379CrossRefPubMed

57.

Tuttle KR, Bruton JL, Perusek MC, Lancaster JL, Kopp DT, DeFronzo RA (1991) Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus. N Engl J Med 324(23):1626–1632. https://doi.org/10.1056/NEJM199106063242304CrossRefPubMed

58.

Tuttle KR, Bruton JL (1992) Effect of insulin therapy on renal hemodynamic response to amino acids and renal hypertrophy in non-insulin-dependent diabetes. Kidney Int 42(1):167–173. https://doi.org/10.1038/ki.1992.274CrossRefPubMed

59.

Rhee CM, Kalantar-Zadeh K, Tuttle KR (2022) Novel approaches to hypoglycemia and burnt-out diabetes in chronic kidney disease. Curr Opin Nephrol Hypertens 31(1):72–81. https://doi.org/10.1097/MNH.0000000000000756CrossRefPubMedPubMedCentral

60.

Cole JB, Florez JC (2020) Genetics of diabetes mellitus and diabetes complications. Nat Rev Nephrol 16(7):377–390. https://doi.org/10.1038/s41581-020-0278-5CrossRefPubMedPubMedCentral

61.

Salem RM, Todd JN, Sandholm N, Cole JB, Chen WM, Andrews D et al (2019) Genome-wide association study of diabetic kidney disease highlights biology involved in glomerular basement membrane collagen. J Am Soc Nephrol 30(10):2000–2016. https://doi.org/10.1681/ASN.2019030218CrossRefPubMedPubMedCentral

62.

Lv W, Booz GW, Wang Y, Fan F, Roman RJ (2018) Inflammation and renal fibrosis: Recent developments on key signaling molecules as potential therapeutic targets. Eur J Pharmacol 820:65–76. https://doi.org/10.1016/j.ejphar.2017.12.016CrossRefPubMed

63.

Borza CM, Bolas G, Bock F, Zhang X, Akabogu FC, Zhang MZ et al (2022) DDR1 contributes to kidney inflammation and fibrosis by promoting the phosphorylation of BCR and STAT3. JCI Insight. https://doi.org/10.1172/jci.insight.150887CrossRefPubMedPubMedCentral

64.

Pichler R, Afkarian M, Dieter BP, Tuttle KR (2017) Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets. Am J Physiol Renal Physiol 312(4):F716–F731. https://doi.org/10.1152/ajprenal.00314.2016CrossRefPubMed

65.

Wong MG, Perkovic V, Chalmers J, Woodward M, Li Q, Cooper ME et al (2016) Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON. Diabetes Care 39(5):694–700. https://doi.org/10.2337/dc15-2322CrossRefPubMed

66.

Zhao L, Zou Y, Liu F (2020) Transforming growth factor-beta1 in diabetic kidney disease. Front Cell Dev Biol 8:187. https://doi.org/10.3389/fcell.2020.00187CrossRefPubMedPubMedCentral

67.

Brasacchio D, Okabe J, Tikellis C, Balcerczyk A, George P, Baker EK et al (2009) Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes 58(5):1229–1236. https://doi.org/10.2337/db08-1666CrossRefPubMedPubMedCentral

68.

Kolm-Litty V, Sauer U, Nerlich A, Lehmann R, Schleicher ED (1998) High glucose-induced transforming growth factor beta1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. J Clin Invest 101(1):160–169. https://doi.org/10.1172/JCI119875CrossRefPubMedPubMedCentral

69.

Nathan C, Cunningham-Bussel A (2013) Beyond oxidative stress: an immunologist’s guide to reactive oxygen species. Nat Rev Immunol 13(5):349–361. https://doi.org/10.1038/nri3423CrossRefPubMedPubMedCentral

70.

Anderberg RJ, Meek RL, Hudkins KL, Cooney SK, Alpers CE, Leboeuf RC et al (2015) Serum amyloid A and inflammation in diabetic kidney disease and podocytes. Lab Invest 95(3):250–262. https://doi.org/10.1038/labinvest.2014.163CrossRefPubMed

71.

Sakai N, Wada T (2015) Revisiting inflammation in diabetic nephropathy: the role of the Nlrp3 inflammasome in glomerular resident cells. Kidney Int 87(1):12–14. https://doi.org/10.1038/ki.2014.322CrossRefPubMed

72.

Shahzad K, Bock F, Dong W, Wang H, Kopf S, Kohli S et al (2015) Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy. Kidney Int 87(1):74–84. https://doi.org/10.1038/ki.2014.271CrossRefPubMed

73.

van Bommel EJM, Lytvyn Y, Perkins BA, Soleymanlou N, Fagan NM, Koitka-Weber A et al (2020) Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function. Kidney Int 97(4):631–635. https://doi.org/10.1016/j.kint.2019.12.021CrossRefPubMed

74.

Marrero MB, Banes-Berceli AK, Stern DM, Eaton DC (2006) Role of the JAK/STAT signaling pathway in diabetic nephropathy. Am J Physiol Renal Physiol 290(4):F762–F768. https://doi.org/10.1152/ajprenal.00181.2005CrossRefPubMed

75.

Huang JS, Guh JY, Chen HC, Hung WC, Lai YH, Chuang LY (2001) Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells. J Cell Biochem 81(1):102–113. https://doi.org/10.1002/1097-4644(20010401)81:1〈102::aid-jcb1027〉3.0.co;2‑yCrossRefPubMed

76.

Brosius FC, Tuttle KR, Kretzler M (2016) JAK inhibition in the treatment of diabetic kidney disease. Diabetologia 59(8):1624–1627. https://doi.org/10.1007/s00125-016-4021-5CrossRefPubMedPubMedCentral

77.

Dai C, Stolz DB, Kiss LP, Monga SP, Holzman LB, Liu Y (2009) Wnt/beta-catenin signaling promotes podocyte dysfunction and albuminuria. J Am Soc Nephrol 20(9):1997–2008. https://doi.org/10.1681/ASN.2009010019CrossRefPubMedPubMedCentral

78.

Tan RJ, Zhou D, Zhou L, Liu Y (2011) Wnt/beta-catenin signaling and kidney fibrosis. Kidney Int Suppl 4(1):84–90. https://doi.org/10.1038/kisup.2014.16CrossRef

79.

Eckel RH, Alberti KG, Grundy SM, Zimmet PZ (2010) The metabolic syndrome. Lancet 375(9710):181–183. https://doi.org/10.1016/S0140-6736(09)61794-3CrossRefPubMed

80.

Ganz MJ, Bender ST, Gross C, Bose K, Mertens PR, Scurt FG (2022) Metabolisches Syndrom und Nierenkrankheiten. Nephrologie 17(5):291–303. https://doi.org/10.1007/s11560-022-00595-6CrossRef

81.

Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M et al (2020) A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 73(1):202–209. https://doi.org/10.1016/j.jhep.2020.03.039CrossRefPubMed

82.

Godoy-Matos AF, Silva Junior WS, Valerio CM (2020) NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetol Metab Syndr 12:60. https://doi.org/10.1186/s13098-020-00570-yCrossRefPubMedPubMedCentral

83.

Scurt FG, Bose K, Canbay A, Mertens PR, Chatzikyrkou C (2021) Chronic kidney injury in patients with liver diseases—reappraising pathophysiology and treatment options. Z Gastroenterol 59(6):560–579. https://doi.org/10.1055/a-1402-1502CrossRefPubMed

84.

Xia MF, Bian H, Gao X (2019) NAFLD and diabetes: two sides of the same coin? Rationale for gene-based personalized NAFLD treatment. Front Pharmacol 10:877. https://doi.org/10.3389/fphar.2019.00877CrossRefPubMedPubMedCentral

85.

Targher G, Bertolini L, Rodella S, Lippi G, Zoppini G, Chonchol M (2010) Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol 5(12):2166–2171. https://doi.org/10.2215/CJN.05050610CrossRefPubMedPubMedCentral

86.

Tang SC (2010) Diabetic nephropathy: a global and growing threat. Hong Kong Med J 16(4):244–245PubMed

87.

Espinel E, Agraz I, Ibernon M, Ramos N, Fort J, Seron D (2015) Renal biopsy in type 2 diabetic patients. J Clin Med 4(5):998–1009. https://doi.org/10.3390/jcm4050998CrossRefPubMedPubMedCentral

88.

Scurt FG, Bose K, Canbay A, Mertens PR, Chatzikyrkou C (2020) Paradigm shift in understanding acute kidney injury in patients with chronic liver disease: from pathophysiology to defining disease entities. Z Gastroenterol 58(3):254–266. https://doi.org/10.1055/a-1088-1582CrossRefPubMed

89.

Dillmann WH (2019) Diabetic cardiomyopathy. Circ Res 124(8):1160–1162. https://doi.org/10.1161/CIRCRESAHA.118.314665CrossRefPubMedPubMedCentral

90.

Palazzuoli A, Iacoviello M (2022) Diabetes leading to heart failure and heart failure leading to diabetes: epidemiological and clinical evidence. Heart Fail Rev. https://doi.org/10.1007/s10741-022-10238-6CrossRefPubMedPubMedCentral

91.

Braunwald E (2019) Diabetes, heart failure, and renal dysfunction: The vicious circles. Prog Cardiovasc Dis 62(4):298–302. https://doi.org/10.1016/j.pcad.2019.07.003CrossRefPubMed

92.

Verma S, Wanner C, Zwiener I, Ofstad AP, George JT, Fitchett D et al (2019) Influence of microvascular disease on cardiovascular events in type 2 diabetes. J Am Coll Cardiol 73(21):2780–2782. https://doi.org/10.1016/j.jacc.2019.03.002CrossRefPubMed

93.

Sandesara PB, O’Neal WT, Kelli HM, Samman-Tahhan A, Hammadah M, Quyyumi AA et al (2018) The prognostic significance of diabetes and microvascular complications in patients with heart failure with preserved ejection fraction. Diabetes Care 41(1):150–155. https://doi.org/10.2337/dc17-0755CrossRefPubMed

94.

Maack C, Lehrke M, Backs J, Heinzel FR, Hulot JS, Marx N et al (2018) Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology. Eur Heart J 39(48):4243–4254. https://doi.org/10.1093/eurheartj/ehy596CrossRefPubMedPubMedCentral

Titel: Pathomechanismen der chronischen Nierenschädigung bei Diabetes und anderen Begleiterkrankungen
verfasst von: Maximilian J. Ganz
Katrin Bose
Carolin Herzog
S. Bender
Peter R. Mertens
Florian G. Scurt
Publikationsdatum: 10.03.2023
Verlag: Springer Medizin
Schlagwörter: Typ-2-Diabetes
Typ-1-Diabetes
Diabetische Nephropathie
Chronische Nierenerkrankung
Diabetes mellitus
Hyperglykämie
Albuminurie
Erschienen in: Die Diabetologie / Ausgabe 3/2023
Print ISSN: 2731-7447
Elektronische ISSN: 2731-7455
DOI: https://doi.org/10.1007/s11428-023-01020-9

Praxisempfehlungen der Deutschen Diabetes Gesellschaft

Kurz, prägnant und aktuell: Die Praxisempfehlungen der Deutschen Diabetes Gesellschaft.

Zu den Praxisempfehlungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2023

DDG Praxisempfehlungen: Diabetisches Fußsyndrom

Einfache Indizes zur Beurteilung des kardiovaskulären Risikos

Zeitensprung bei der Diagnostik und Behandlung diabetischer Nierenschäden

DDG Praxisempfehlungen: Nephropathie bei Diabetes

Metabolisches Gedächtnis bei diabetischer Nierenerkrankung

Mitteilungen des BDE

Praxisempfehlungen der Deutschen Diabetes Gesellschaft